Please use this identifier to cite or link to this item:

TitlePTX3 Polymorphisms Influence Cytomegalovirus Reactivation After Stem-Cell Transplantation
Author(s)Campos, Cláudia F.
Leite, Luís
Pereira, Paulo
Vaz, Carlos Pinho
Branca, Rosa
Campilho, Fernando
Freitas, Fátima
Ligeiro, Dário
Marques, António
Torrado, Egídio
Silvestre, Ricardo Jorge Leal
Lacerda, João F.
Campos Jr., António
Cunha, Cristina
Carvalho, Agostinho
stem-cell transplantation
single nucleotide polymorphism
precision medicine
Issue date2019
PublisherFrontiers Media
JournalFrontiers in Immunology
CitationCampos, C. F., Leite, L., Pereira, P., Vaz, C. P., et. al. (2019). PTX3 polymorphisms influence cytomegalovirus reactivation after stem-cell transplantation. Frontiers in immunology, 10, 88.
Abstract(s)Background: Reactivation of latent human cytomegalovirus (CMV) in patients undergoing allogeneic stem-cell transplantation (HSCT) predisposes to several clinical complications and is therefore a major cause of morbidity and mortality. Although pentraxin-3 (PTX3) has been previously described to bind both human and murine CMV and mediate several host antiviral mechanisms, whether genetic variation in the PTX3 locus influences the risk of CMV infection is currently unknown. Methods: To dissect the contribution of genetic variation within PTX3 to the development of CMV infection, we analyzed described loss-of-function variants at the PTX3 locus in 394 recipients of HSCT and their corresponding donors and assessed the associated risk of CMV reactivation. Results: We report that the donor, but not recipient, h2/h2 haplotype in PTX3 increased the risk of CMV reactivation after 24 months following transplantation, with a significant effect on survival. Among recipients with h2/h2 donors, CMV seropositive patients as well as those receiving grafts from unrelated donors, regardless of the CMV serostatus, were more prone to develop viral reactivation after transplantation. Most importantly, the h2/h2 haplotype was demonstrated to display an influence toward risk of CMV reactivation comparable to that conferred by the unrelated status of the donor alone. Conclusions: Our findings demonstrate the important contribution of genetic variation in donor PTX3 to the risk of CMV reactivation in patients undergoing HSCT, highlighting a promising prognostic value of donor PTX3 to predict risk of CMV reactivation in this clinical setting.
Publisher version
AccessOpen access
Appears in Collections:ICVS - Artigos em Revistas Internacionais com Referee

Files in This Item:
File Description SizeFormat 
Campos CF et al. Front Immunol.pdf1,31 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID